Celecoxib for osteoarthritis, rheumatoid arthritis, and acute pain management

Celecoxib is a prescription nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation in various arthritis conditions and acute pain scenarios. It is available as oral capsules in 50 mg, 100 mg, and 200 mg strengths, designed for short-term use to manage symptoms associated with osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea.

Celecoxib is approved for:

• Managing signs and symptoms of osteoarthritis (OA) in adults.
• Managing signs and symptoms of rheumatoid arthritis (RA) in adults.
• Managing signs and symptoms of juvenile rheumatoid arthritis (JRA) in patients aged 2 years and older.
• Managing signs and symptoms of ankylosing spondylitis (AS) in adults.
• Relief of acute pain in adults.
• Management of primary dysmenorrhea in adult women.

Celecoxib

Celecoxib works by selectively inhibiting the cyclooxygenase-2 (COX-2) enzyme, which plays a key role in the production of prostaglandins that cause inflammation and pain. By reducing COX-2 activity, celecoxib helps alleviate inflammation and pain associated with arthritis and other acute conditions.

General dosing instructions

• Use the lowest effective dose for the shortest possible duration to meet treatment goals.
• Doses can be taken with or without regard to meals.

Specific dosages by indication

• Osteoarthritis (OA): 200 mg once daily or 100 mg twice daily.
• Rheumatoid arthritis (RA): 100 mg to 200 mg twice daily.
• Juvenile rheumatoid arthritis (JRA) (patients ≥2 years): For weight 10–25 kg, 50 mg twice daily; for >25 kg, 100 mg twice daily. Capsule contents may be mixed with applesauce if needed and consumed immediately; stability on applesauce is up to 6 hours if refrigerated.
• Ankylosing spondylitis (AS): 200 mg once daily (single or divided dose). If no response after 6 weeks, trial of 400 mg daily may be considered, but if ineffective after further 6 weeks, consider alternative treatments.
• Acute pain and primary dysmenorrhea: Initial dose 400 mg, followed by 200 mg if needed on first day; subsequent days, 200 mg twice daily as needed.

Special populations

• Hepatic impairment (moderate, Child-Pugh Class B): Reduce dose by 50%. Use not recommended in severe hepatic impairment.
• Poor CYP2C9 metabolizers: Initiate therapy at half the lowest recommended dose or consider alternative treatments in JRA patients.

• Known hypersensitivity to celecoxib or any component of the product.
• History of asthma, urticaria, or allergic reactions to aspirin or other NSAIDs.
• Aspirin-sensitive asthma.
• Use during coronary artery bypass graft (CABG) surgery.
• Known hypersensitivity to sulfonamides.

Serious cardiovascular risks

NSAIDs, including celecoxib, increase the risk of serious cardiovascular thrombotic events such as myocardial infarction and stroke, which can be fatal. This risk may occur early and increases with longer duration of use. Celecoxib is contraindicated for use during coronary artery bypass graft (CABG) surgery.

Gastrointestinal risks

Serious GI adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, can occur at any time without warning and may be fatal. Elderly patients and those with prior history of GI bleeding or ulcers have a higher risk.

Hypersensitivity and allergic reactions

Contraindicated in patients with known allergy to celecoxib, sulfonamides, or those with aspirin-sensitive asthma due to risk of severe anaphylactic reactions.

Other warnings

• Monitor liver function; discontinue if signs of hepatotoxicity develop.
• Monitor blood pressure; NSAIDs may worsen hypertension or reduce effects of antihypertensives.
• Avoid in severe heart failure unless benefits outweigh risks; monitor for worsening heart failure.
• Use cautiously in patients with renal impairment; monitor renal function and correct volume status prior to treatment.
• Potential for hyperkalemia; monitor serum potassium as necessary.
• Discontinue use immediately if serious skin reactions or drug reaction with eosinophilia and systemic symptoms (DRESS) occur.
• Limit use during pregnancy from 20 weeks gestation due to fetal risks.

Common side effects

• Elevations of liver enzymes (ALT or AST) occasionally occur.
• Peripheral edema and fluid retention have been reported.

Serious side effects

• Serious cardiovascular events including myocardial infarction and stroke.
• Serious gastrointestinal bleeding, ulceration, and perforation.
• Severe hypersensitivity and anaphylaxis.
• Severe hepatotoxicity including liver failure.
• Serious skin reactions requiring immediate discontinuation.

• May impair efficacy of antihypertensives like ACE inhibitors, thiazide and loop diuretics.
• Concurrent use with aspirin increases risk of serious GI bleeding.
• Potential additive risk of renal toxicity with diuretics, ACE inhibitors, or angiotensin receptor blockers.

Pregnancy

Use of celecoxib and other NSAIDs should be limited between approximately 20 to 30 weeks of pregnancy due to risk of fetal renal dysfunction and oligohydramnios. Avoid use at about 30 weeks gestation and later due to risks of premature closure of the fetal ductus arteriosus.

Contraception/Fetal risk

Not described in detail.

Lactation

Not described in detail.